FDA approves Arcutis' roflumilast cream for plaque psoriasis in children 2+
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
